Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,694 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06989541Recruiting
Immunoglobulin for low antibodies after CAR T-cell therapy
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06990087RecruitingPhase 2
T-cell therapy for progressive multifocal leukoencephalopathy (PML)
This trial tests a T-cell therapy for people with PML, a rare brain infection. It aims to boost your immune system to fight the virus causing PML. You may be eligible if you have PML not caused by HIV, natalizumab, or certain recent treatments.
München, BavariaAges 18 years+ - NCT06993675RecruitingPhase 2
T-cell therapy for MRD in newly diagnosed myeloma patients after transplant
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
New Haven, ConnecticutAges 18 years+ - NCT06994143RecruitingPhase 1
A study of CLN-978 for rheumatoid arthritis
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
ErlangenAges 18 years+ - NCT06999031RecruitingEarly Phase 1
CG-105-12 for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
Nanchang, JiangxiAges 18–75 - NCT07000617RecruitingPhase 2
A study of drugs plus radiation for early-stage NK/T-cell lymphoma
This trial tests a combination of the drugs dexamethasone, azacitidine, pegaspargase, and tislelizumab along with radiation therapy for people with stage I or II extranodal NK/T-cell lymphoma. The goal is to see if this treatment works well and is safe for patients who have not yet received treatment.
BeijingAges 18 years+ - NCT07003490Recruiting
Lung cancer surgery with removal of lymph nodes on the other side
This study looks at whether removing lymph nodes from the opposite side of the chest during surgery can help people with advanced lung cancer that has spread to the lymph nodes in the middle of the chest. It may offer a more thorough treatment for patients who are healthy enough for surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07008287Recruiting
Taletrectinib for ROS1+ lung cancer with brain spread
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hangzhou, ZhejiangAges 18 years+ - NCT07012720Recruiting
Comparing breast cancer treatments before surgery
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
Xi'an, ShaanxiAges 25–75 - NCT07013565RecruitingPhase 2
Chemoimmunotherapy for ALK+ ALCL that has come back
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
Valhalla, New YorkAges 1–39 - NCT07015437RecruitingPhase 2
Testing the recovery and lifespan of treated red blood cells
This study tests a new way to treat donated red blood cells (called INTERCEPT) to see how long they survive in the body and how well they recover. It may help make blood transfusions safer for people who need them.
Cincinnati, OhioAges 18 years+ - NCT07016126RecruitingPhase 3
Study of D-BACE, chemo, and carlizumab for lung cancer
This trial tests a combination of a new drug (D-BACE), chemotherapy, and carlizumab for people with a certain type and stage of lung cancer that can be removed with surgery. It aims to see if this combination helps shrink tumors and improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07016997RecruitingPhase 1
A study of CBA-1535 for advanced solid tumors
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Nagaizumicho, ShizuokaAges 20 years+ - NCT07019220RecruitingPhase 2
Chemoablation for low-risk bladder cancer
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
ViennaAges 18 years+ - NCT07020169Recruiting
Using AI 3D kidney models to guide partial nephrectomy
This trial tests if a 3D kidney model made with artificial intelligence helps surgeons remove a kidney tumor (partial nephrectomy) more precisely. It may help preserve healthy kidney tissue while treating the cancer.
Nanjing, JiangsuAges 18–80 - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07024680Recruiting
Sunitinib or sorafenib for papillary kidney cancer
This study looks at how well sunitinib or sorafenib work as a first treatment for a type of kidney cancer called papillary renal cell carcinoma (PRCC) that cannot be removed with surgery or has spread. It aims to understand real-world results in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07026110Recruiting
PET/CT for distinguishing non-small cell lung cancer
This study uses a special PET/CT scan to better tell if a lung nodule is non-small cell lung cancer. If you have a solid nodule in your lung that's at least 8 mm and might be cancer, this scan could help get a clearer diagnosis.
ShanghaiAges 18–80 - NCT07029152Recruiting
Anal cancer screening for gay and bisexual men on PrEP
This study is screening gay and bisexual men for anal cancer by taking a swab sample. It aims to find early signs of cancer so it can be treated early.
BrugesAges 35 years+ - NCT07029217RecruitingPhase 3
Lower radiation dose study for B-cell lymphomas
This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT07030400Recruiting
Quality of life study for adults with CLL or SLL
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
Tampa, FloridaAges 18 years+ - NCT07035002RecruitingPhase 1
PD-1 knockout TILs for advanced colorectal cancer
This trial tests a new therapy where immune cells (TILs) from your tumor are modified to fight cancer more effectively. It's for people with advanced colorectal cancer who can't get standard treatments.
Shanghai, None SelectedAges 18–70 - NCT07035938Recruiting
T-Cell Health in Blood Cancer Patients Study
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
Xiamen, FujianAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,694 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.